<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02466581</url>
  </required_header>
  <id_info>
    <org_study_id>CO-STAR</org_study_id>
    <secondary_id>2014-002374-36</secondary_id>
    <secondary_id>2014/1705-31/3</secondary_id>
    <nct_id>NCT02466581</nct_id>
  </id_info>
  <brief_title>Dose Reduction for Early Rheumatoid Arthritis Patients With Low Disease Activity</brief_title>
  <official_title>A Multicenter, Randomized, Open-label, Blinded-assessor, Follow-up, Phase 4 Study in Patients With Rheumatoid Arthritis Who Have Completed the Initial Treatment Part in the NORD-STAR Study and Have Reached Stable Low Disease Activity</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Karolinska Institutet</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Karolinska Institutet</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an international (Nordic) trial designed to compare the safety and efficacy of active&#xD;
      conventional therapy (ACT) and three biologic treatments (Certolizumab-pegol, Abatacept or&#xD;
      Tocilizumab) in subjects with early rheumatoid arthritis (RA). The global aim of this study&#xD;
      is to assess and compare two alternative de-escalation strategies in patients who achieved&#xD;
      low disease activity during first-line therapy in the NORD-STAR study.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      25 patients have been included in the study of which 1 has had an early termination an 22&#xD;
      have completed the full study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">February 3, 2015</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Actual">January 22, 2020</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of patients maintaining low disease activity after dose reduction</measure>
    <time_frame>24 weeks after dose reduction</time_frame>
    <description>The proportion of patients, with early dose reduction vs late dose reduction, who maintain low disease activity (2.8 &lt; CDAI ≤ 10.0) at the time point 24 weeks after the dose was first reduced.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">25</enrollment>
  <condition>Rheumatoid Arthritis</condition>
  <arm_group>
    <arm_group_label>Arm 1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients keep the intervention they had in the NORD-STAR-study (NCT01491815), i.e. one of the four below:&#xD;
Sulphasalazine + Hydroxychloroquine OR Prednisolone plus Methotrexate and steroids&#xD;
Cimzia plus Methotrexate and steroids&#xD;
Orencia plus Methotrexate and steroids&#xD;
RoActemra plus Methotrexate and steroids&#xD;
This intervention is de-escalated starting at randomization.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients keep the intervention they had in the NORD-STAR-study (NCT01491815), i.e. one of the four below:&#xD;
Sulphasalazine + Hydroxychloroquine OR Prednisolone plus Methotrexate and steroids&#xD;
Cimzia plus Methotrexate and steroids&#xD;
Orencia plus Methotrexate and steroids&#xD;
RoActemra plus Methotrexate and steroids&#xD;
This intervention is de-escalated starting 24 weeks after randomization.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sulphasalazine + Hydroxychloroquine OR Prednisolone</intervention_name>
    <description>Methotrexate: 25mg/week. SSZ: 2 g/day. HCQ: 35 mg/kg/week (Finland and Denmark) Methotrexate: 25mg/week. Prednisolone 20 mg/day tapered in 9 weeks to 5 mg/day, discontinued after 9 months. (Sweden, Norway, and Iceland)</description>
    <arm_group_label>Arm 1</arm_group_label>
    <arm_group_label>Arm 2</arm_group_label>
    <other_name>SSZ+HCQ or Prednisolone</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Cimzia</intervention_name>
    <description>Certolizumab-pegol: 200 mg s.c. every other week. Methotrexate: 25mg/week</description>
    <arm_group_label>Arm 1</arm_group_label>
    <arm_group_label>Arm 2</arm_group_label>
    <other_name>Certolizumab-pegol</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Orencia</intervention_name>
    <description>Abatacept: 125 mg s.c. every week. Methotrexate: 25mg/week</description>
    <arm_group_label>Arm 1</arm_group_label>
    <arm_group_label>Arm 2</arm_group_label>
    <other_name>Abatacept</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>RoActemra</intervention_name>
    <description>Tocilizumab is given as 4-weekly infusions at dosage 8 mg/kg or 162 mg in solution s.c. every week. Methotrexate: 25mg/week</description>
    <arm_group_label>Arm 1</arm_group_label>
    <arm_group_label>Arm 2</arm_group_label>
    <other_name>Tocilizumab</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Subject has been enrolled in the NORD-STAR study according to that study inclusion&#xD;
             criteria (and did not meet any of the exclusion criteria in that study).&#xD;
&#xD;
          2. Subject has low-disease-activity according to: 2.8 &lt; CDAI ≤ 10.0, from week 56 in the&#xD;
             NORD-STAR study, i.e. during 24 weeks before randomization.&#xD;
&#xD;
          3. Subject has not more than 3 tender out of the 28 joints.&#xD;
&#xD;
          4. According to the investigators opinion the remaining findings are not due to&#xD;
             significant active disease (RA).&#xD;
&#xD;
          5. Female subject is either not of childbearing potential (postmenopausal, surgically&#xD;
             sterile etc.), or is of childbearing potential and practicing one of the following&#xD;
             methods of birth control throughout the study and for 150 days after study completion:&#xD;
&#xD;
               -  Intrauterine device (IUD)&#xD;
&#xD;
               -  Contraceptives (oral, parenteral, patch) for three months prior to study drug&#xD;
                  administration)&#xD;
&#xD;
               -  A vasectomized partner&#xD;
&#xD;
          6. Subject is judged to be in good general health as determined by the principal&#xD;
             investigator.&#xD;
&#xD;
          7. Subject must be able and willing to provide written informed consent and comply with&#xD;
             the requirements of this study protocol.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Subject has left the NORD-STAR study due to moderate or high disease activity (CDAI ≥&#xD;
             10.0) or for other medically important event(s).&#xD;
&#xD;
          2. Patient is eligible for treatment part 2 (A or B) in the NORD-STAR study.&#xD;
&#xD;
          3. Active infection of any kind (excluding fungal infections of nail beds), or any major&#xD;
             episode of infection requiring hospitalization within 4 weeks prior to randomization.&#xD;
&#xD;
          4. Subject has a poorly controlled medical condition, such as uncontrolled diabetes,&#xD;
             unstable heart disease, congestive heart failure, recent cerebrovascular accidents and&#xD;
             any other condition which, in the opinion of the investigator, would put the subject&#xD;
             at risk by participation in the study.&#xD;
&#xD;
          5. Subject has a history of clinically significant hematologic (e.g., severe anemia,&#xD;
             leukopenia, thrombocytopenia), renal or liver disease (e.g., fibrosis, cirrhosis,&#xD;
             hepatitis).&#xD;
&#xD;
          6. Subject has history of neurologic symptoms suggestive of central nervous system (CNS)&#xD;
             demyelinating disease and/or diagnosis of central demyelinating disease.&#xD;
&#xD;
          7. Subject has history of cancer or lymphoproliferative disease. Allowable exceptions:&#xD;
&#xD;
               1. Successfully treated cutaneous squamous cell or basal cell carcinoma&#xD;
&#xD;
               2. Localized carcinoma in situ of the cervix&#xD;
&#xD;
               3. Curatively treated malignancy (treatment terminated) &gt; 5 years prior to&#xD;
                  randomization.&#xD;
&#xD;
          8. Subject has a history of listeriosis, histoplasmosis, untreated TB, persistent chronic&#xD;
             infections, or recent active infections requiring hospitalization or treatment with&#xD;
             intravenous (i.v.) anti-infectives within 30 days or oral anti-infectives within 14&#xD;
             days prior to randomization.&#xD;
&#xD;
          9. Female subject who is pregnant or breast-feeding or considering becoming pregnant&#xD;
             during the study or within 150 days after the last dose of study medication.&#xD;
&#xD;
         10. Men who are planning to father a child during the time they are included in the study.&#xD;
&#xD;
         11. Subject has a history of clinically significant drug or alcohol usage in the last&#xD;
             year.&#xD;
&#xD;
         12. Subject has a chronic widespread pain syndrome.&#xD;
&#xD;
         13. Subject is considered by the investigator, for any reason, to be an unsuitable&#xD;
             candidate for the study.&#xD;
&#xD;
         14. Subject is unwilling to comply with the study protocol.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ronald van Vollenhoven, MD, Prof.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Karolinska Institutet</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Sahlgrenska University Hospital</name>
      <address>
        <city>Gothenburg</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Karolinska University Hospital</name>
      <address>
        <city>Huddinge</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Linköping University Hospital</name>
      <address>
        <city>Linköping</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Skåne University Hospital</name>
      <address>
        <city>Lund</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Skåne University Hospital</name>
      <address>
        <city>Malmö</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Karolinska University Hospital</name>
      <address>
        <city>Solna</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Karolinska Institutet</name>
      <address>
        <city>Stockholm</city>
        <zip>171 76</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Academic Specialist Center</name>
      <address>
        <city>Stockholm</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Sweden</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>May 29, 2015</study_first_submitted>
  <study_first_submitted_qc>June 8, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 9, 2015</study_first_posted>
  <last_update_submitted>February 28, 2021</last_update_submitted>
  <last_update_submitted_qc>February 28, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 2, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Karolinska Institutet</investigator_affiliation>
    <investigator_full_name>Ronald van Vollenhoven, prof.</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Arthritis, Rheumatoid</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hydroxychloroquine</mesh_term>
    <mesh_term>Sulfasalazine</mesh_term>
    <mesh_term>Prednisolone</mesh_term>
    <mesh_term>Methylprednisolone Acetate</mesh_term>
    <mesh_term>Methylprednisolone</mesh_term>
    <mesh_term>Methylprednisolone Hemisuccinate</mesh_term>
    <mesh_term>Prednisolone acetate</mesh_term>
    <mesh_term>Abatacept</mesh_term>
    <mesh_term>Certolizumab Pegol</mesh_term>
    <mesh_term>Prednisolone hemisuccinate</mesh_term>
    <mesh_term>Prednisolone phosphate</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

